U.S. Drug Prices Are 278% Higher Than Other Countries. Your Plan Is Paying the Difference.

U.S. employers pay roughly three times what employers in other countries pay for the same drugs. That gap isn't closing. It's widening, and your benefits budget is absorbing the hit.

According to a RAND Corporation study published in PMC, U.S. manufacturer gross drug prices in 2022 were 278% of prices across 33 OECD countries combined. Other countries pay roughly one-third of what we pay. That's not a rounding error. That's a structural problem sitting inside your income statement.

How large is the pricing gap between U.S. and international drug costs?

The RAND data is striking at the headline level. The brand-name numbers are where your plan really bleeds. The same RAND report found U.S. gross prices for brand-name originator drugs were 422% of prices in comparison countries, more than four times higher.

The rebuttal you'll hear from your PBM is that they negotiate rebates. That doesn't close the gap. Even after adjusting for manufacturer rebates, U.S. net prices for brand-name originator drugs were still over three times as high as international prices.

Generics are a different story. They account for 90% of U.S. prescription volume, per ASPE at HHS, and they price competitively. The problem is that brand-name drugs still drive the overall index to 278% because of the dollar volume attached to each script.

One member of your group hitting a specialty drug can cost more than a dozen employees using generics all year. That's the math that matters to a CFO.

What does this look like in actual dollar terms?

The U.S. Senate HELP Committee Minority Drug Pricing Report put specific numbers on it. Tecvayli, a multiple myeloma treatment from Johnson & Johnson, costs $426,000 annually in the U.S. Canada pays $132,000. France and Germany each pay $95,000.

That's the same drug. Same manufacturer. Four and a half times the price. Darzalex, another J&J oncology drug, runs $226,000 per year in the U.S. Canada pays $121,000. France pays $115,000. Germany pays $114,000.

Hernexeos from Boehringer Ingelheim costs $260,000 here and $55,300 in Japan. Nearly five times higher. These aren't edge cases.

ASPE data shows Stelara generated $13.9 billion in U.S. market revenue over the measured period. Enbrel generated $9.1 billion. Self-insured employers are helping fund those numbers every time a claim clears.

Is this getting worse in 2026?

Yes. Manufacturers planned to raise list prices on at least 350 brand-name medications at the start of 2026, according to 3 Axis Advisors. That's up from 250 drugs the prior year, a 40% increase in the number of drugs getting price hikes.

The U.S. already spends 16.6% of GDP on national health care, versus the OECD average of 9.2%, according to Global Legal Insights. That comes out to roughly $13,493 per capita. Employers fund a significant portion of that gap.

With more price increases coming, the baseline keeps moving up. Stop-loss renewals are feeling it too. Stop-loss rates are climbing in 2026 and specialty drug trend is part of the same story.

What can a mid-market employer actually do about this?

You have more options than you think, and fewer than the headlines suggest. Here's what's real for a 100-500 employee group.

Transparent PBM contracting. Your current PBM contract probably isn't passing through 100% of the rebates you think it is. PBM rebate pass-through contract language is the starting point. If you can't audit the spread, you're guessing.

See also what a best-in-class transparent PBM contract actually requires before you sign anything.

Direct sourcing and carve-outs. For high-cost specialty drugs, including GLP-1s, direct sourcing is no longer theoretical. It's operational. Buying GLP-1s without the PBM is a live strategy some mid-market employers are already running.

International reference pricing programs. Some third-party administrators and specialized vendors now offer programs that source maintenance medications from licensed international pharmacies. Savings on maintenance drugs can run 40-70% off U.S. list. This isn't importing drugs illegally. It's using compliant cross-border sourcing programs that have been operating for years.

None of these options work without a broker who's willing to push. Most aren't. That's the real bottleneck for mid-market employers.

Frequently asked questions

Why are U.S. drug prices so much higher than in other countries?

The U.S. doesn't set drug prices the way most other countries do. Other governments negotiate directly with manufacturers and set a national price. The U.S. relies on a fragmented system of PBMs, insurers, and employers each negotiating separately, which gives manufacturers more pricing power. The result is a 278% premium over what 33 OECD countries pay on average.

Do PBM rebates close the gap between U.S. and international drug prices?

No. RAND data shows that even after adjusting for manufacturer rebates, U.S. net prices for brand-name originator drugs are still more than three times higher than international prices. Rebates reduce the gap. They don't close it. And not all rebates make it back to your plan depending on your contract.

What options do self-insured employers have that fully insured employers don't?

Self-insured employers can negotiate PBM contract terms directly, require full rebate pass-through, carve out specific drug categories, and work with vendors that offer international reference pricing programs. Fully insured employers are largely locked into their carrier's formulary and pricing. Self-insured status is the prerequisite for most of these strategies.

Are international reference pricing programs legal for U.S. employers?

Compliant cross-border sourcing programs have been operating in the U.S. for years and are distinct from personal drug importation. Several states have run government-sponsored international sourcing programs. Employers using these programs work through licensed vendors and pharmacies. Your legal and compliance team should review any specific program before implementation.